Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin

N/AApproved For MarketingNCT05031546

Cara Therapeutics, Inc.

Overview

This is an intermediate-size patient population expanded access protocol for the use of intravenous (IV) difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients undergoing hemodialysis.

Visits during the expanded access program will consist of a Baseline Visit to confirm eligibility and an End of Treatment visit. Patients will receive IV difelikefalin at a dose of 0.5 mcg/kg after each dialysis session, generally 3 times per week. The End of Treatment visit will be defined as the first dialysis visit following the last dose of IV difelikefalin under the intermediate-size patient population expanded access protocol.

Study Type

EXPANDED_ACCESS

Conditions

Uremic Pruritus

Interventions

DifelikefalinDRUG

IV Difelikefalin 0.5 mcg/kg administered after each dialysis session (3 times/week)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: * Adults ≥ 18 years old; * Has end-stage renal disease (ESRD) and is currently receiving in-center hemodialysis; * Has moderate-to-severe pruritus attributed to ESRD which is significantly impacting the patient's quality of life; * Has no comparable or satisfactory alternative therapy for the treatment of moderate-to-severe pruritus, as determined by the sponsor-investigator. Key Exclusion Criteria: * Has severe hepatic impairment (Child-Pugh class C), as the influence of severe hepatic impairment on the pharmacokinetics of difelikefalin has not been evaluated; * Is pregnant or nursing; * Has been exposed to any other investigational medication in the past 60 days; * Present any other reason which may lead to an unfavorable risk-benefit ratio for treatment with difelikefalin, as determined by the sponsor-investigator; * Has a known or suspected allergy to difelikefalin or any component of the investigational product.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.